VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection  by Arulanandam, Rozanne et al.
ArticleVEGF-Mediated Induction of PRD1-BF1/Blimp1
Expression Sensitizes Tumor Vasculature to
Oncolytic Virus InfectionGraphical AbstractHighlightsd VEGF/VEGFR2 signaling sensitizes endothelial cells to
oncolytic virus infection
d PRD1-BF1 mediates immune suppression in endothelial cells
downstream of VEGF
d PRD1-BF1 is induced in remodelling vessels by chronic or
transient VEGF stimulation
d Infection of tumor vasculature orchestrated by PRD1-BF1 is
critical for OV deliveryArulanandam et al., 2015, Cancer Cell 28, 210–224
August 10, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.ccell.2015.06.009Authors
Rozanne Arulanandam, Cory
Batenchuk, Fernando A. Angarita, ...,





Arulanandam et al. show that VEGFR2
signaling in remodelling vessels induces
the transcription repressor PRD1-BF1/
Blimp1, which represses the expression
of genes involved in type I interferon-
mediated antiviral signaling, thus
allowing oncolytic virus to infect tumor
vasculatures to further spread within
tumors.
Cancer Cell
ArticleVEGF-Mediated Induction of PRD1-BF1/Blimp1
Expression Sensitizes Tumor Vasculature
to Oncolytic Virus Infection
Rozanne Arulanandam,1 Cory Batenchuk,1 Fernando A. Angarita,2 Kathryn Ottolino-Perry,2 Sophie Cousineau,1
Amelia Mottashed,1 Emma Burgess,1 Theresa J. Falls,1 Naomi De Silva,1 Jovian Tsang,1 Grant A. Howe,1
Marie-Claude Bourgeois-Daigneault,1 David P. Conrad,1 Manijeh Daneshmand,1 Caroline J. Breitbach,3 David H. Kirn,3
Leda Raptis,6 Subash Sad,7 Harold Atkins,1 Michael S. Huh,1 Jean-Simon Diallo,1 Brian D. Lichty,4 Carolina S. Ilkow,1
Fabrice Le Boeuf,1 Christina L. Addison,1 J. Andrea McCart,2,5 and John C. Bell1,*
1Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada
2Toronto General Research Institute (TGRI), University Health Network, Toronto, ON M5G 2M9, Canada
3SillaJen Biotherapeutics, San Francisco, CA 94111-3380, USA
4McMaster Immunology Research Centre, McMaster University, Hamilton, ON L8S 4K1, Canada
5Department of Surgery, Mount Sinai Hospital, University of Toronto, Toronto, ON M5G 1X5, Canada
6Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON K7L 3N6, Canada
7Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
*Correspondence: jbell@ohri.ca
http://dx.doi.org/10.1016/j.ccell.2015.06.009SUMMARYOncolytic viruses designed to attack malignant cells can in addition infect and destroy tumor vascular endo-
thelial cells. We show here that this expanded tropism of oncolytic vaccinia virus to the endothelial compart-
ment is a consequence of VEGF-mediated suppression of the intrinsic antiviral response. VEGF/VEGFR2
signaling through Erk1/2 and Stat3 leads to upregulation, nuclear localization, and activation of the transcrip-
tion repressor PRD1-BF1/Blimp1. PRD1-BF1 does not contribute to the mitogenic effects of VEGF, but
directly represses genes involved in type I interferon (IFN)-mediated antiviral signaling. In vivo suppression
of VEGF signaling diminishes PRD1-BF1/Blimp1 expression in tumor vasculature and inhibits intravenously
administered oncolytic vaccinia delivery to and consequent spread within the tumor.INTRODUCTION
Engineered oncolytic viruses (OVs) are multi-functional anti-
cancer agents advancing deeply into clinical trials and, in some
instances, appear headed for approval (Bell and McFadden,
2014). OVs are designed to exploit unique attributes of the tumor
niche, sincemany of the pathways subverted by the tumor favor-
ing increased survival, immune evasion, deregulated meta-
bolism, and enhanced angiogenesis also compromise the ability
of cancer cells to combat virus infection (reviewed in Ilkow et al.,
2014). Over the last several years, it has become clear that OVs
infect and destroy tumor cells, but in addition prime or re-awaken
existing anti-tumor immune responses (Lichty et al., 2014).Significance
VEGF secretion within the tumor microenvironment fuels mali
cover and characterize a signaling cascade initiated by VEGF,
in activated endothelial cells. Constitutive VEGF signaling, with
ical determinant of oncolytic virus tropism to tumor blood vesse
growth equally provides an opportunity for destruction of tum
therapeutic efficacy.
210 Cancer Cell 28, 210–224, August 10, 2015 ª2015 Elsevier Inc.Furthermore, some OV platforms have the ability to specifically
infect and destroy tumor vasculature (Breitbach et al., 2011a).
For instance, systemic delivery of the oncolytic vaccinia virus
Pexa-Vec in cancer patients leads to the infection of tumor
vasculature and impairment of tumor perfusion in a largepercent-
age of treated patients (Breitbach et al., 2011b, 2013). Tumor
neo-vasculature is distinct in several ways from normal blood
vessels as a result of chronic exposure to pro-angiogenic cyto-
kines secreted by cancer cells (Chung et al., 2010). The goal of
this study was to characterize the signaling events triggered by
vascular endothelial growth factor (VEGF) capable of antago-
nizing cellular antiviral responses, thereby uniquely sensitizing tu-
mor endothelial cells to oncolytic virus infection and destruction.gnant cell growth by promoting angiogenesis. Here we un-
leading to direct suppression of the innate antiviral response
in the context of pathological vascular remodelling, is a crit-
ls. Thus, pathological VEGF signalingwhile promoting tumor
or vasculature by oncolytic viruses, thereby increasing their
RESULTS
VEGF/VEGFR2 Signaling Sensitizes Tumor Vasculature
to Infection by Oncolytic Viruses
To investigate the sensitivity of tumor vascular endothelial
cells to OV infection, we systemically administered an RFP-
expressing, mouse-adapted, oncolytic version of vaccinia
virus (vvDD-RFP; 1E9 PFU) into C57BL/6 mice bearing MC38
colon carcinoma tumors seeded under a dorsal window
chamber. Live confocal tumor microscopy revealed overlap of
vvDD-RFP fluorescence and anti-CD31-APC-labeled tumor
vasculature (Figure 1A). Quantitative immunohistochemistry
(IHC) established that vvDD staining was detected in tumor
cells and 25% of CD31+ vessels (Figure 1B). Systemic
administration of OV did not result in the infection of normal
tissue or vasculature found in the lung, liver, and kidney
(Figure 1B).
The replication of vvDD-RFP within human umbilical vein
endothelial cells (HUVECs) was enhanced in the presence of
MC38-conditioned media (MC38 CM). MC38 colon carcinoma
cells express and secrete VEGF-A to form highly vascularized tu-
mors in syngeneic C57BL/6 mice (Zhai et al., 1999). A similar in-
crease in vvDD replication was observed in HUVECs treated with
recombinant mouse VEGF-A alone (mVEGFA; Figures 1C and
1D). A comparable increase in the infectivity of a GFP-expressing
version of the clinical trial candidate Pexa-Vec, WyTK/GFP+
(Breitbach et al., 2011b), was observed in HUVECs grown in
conditioned media from human VEGF secreting Caki-1 renal
carcinoma cells (Caki-1 CM) or human recombinant VEGF-A
(VEGF165; Figures 1E and 1F). The VEGFR inhibitor brivanib
(Cai et al., 2008) and the hVEGF-neutralizing monoclonal anti-
body bevacizumab blocked conditionedmedia and recombinant
VEGF-A enhancement of vaccinia virus replication (Figures 1C–
1F) and activation of the VEGF pathway (Figures 1G and S1).
Interestingly, the VEGF-mediated enhancement of vaccinia
virus replication was observed in other VEGFR2-expressing
cell lines including human dermal microvascular endothelial cells
(HDMECs) and MDA-MB-231 human breast cancer cells (Fig-
ures 1H and 1I). Caki-1 cells, which do not express VEGFR2
(Keyes et al., 2003), did not increase viral output in the presence
of VEGF (Figure 1J). These data demonstrate that direct VEGF/
VEGFR2 activation is a prerequisite for sensitizing vascular
endothelial cells to oncolytic vaccinia virus replication.
VEGF Signaling Promotes a Repression of the Type I
Interferon Immune Response in Endothelial Cells
To identify pathways downstream of VEGFR2 that render
endothelial cells sensitive to oncolytic vaccinia infection, we
carried out a global gene expression analysis comparing OV-
infected HUVECs treated with VEGF165 against OV-infected,
mock-treated controls. Microarray analysis of VEGF165-treated
HUVECs infected with WyTK/GFP+ revealed changes in
gene expression that were strongly associated with two major
gene ontology (GO) classes. Genes upregulated by VEGF165 in
the context of infection were strongly associated with GO classi-
fications involved in cell-cycle processes (Figure 2A, left). How-
ever, we also found that VEGF treatment of infected HUVECs
led to repression of the type I interferon (IFN) response (Figure 2A,
right). Consistent with this finding, we found that, in addition tooncolytic vaccinia, other type I IFN-sensitive OV strains, such
as herpes simplex virus (HSV), lacking one copy of ɣ34.5, the
rhabdoviruses VSVD51, and Maraba virus MG1 (Brun et al.,
2010; Stojdl et al., 2003), demonstrated enhanced infectivity in
HUVECs when treated with Caki-1 CM or hVEGF165 (Figures
S2A–S2C). Moreover, VEGF treatment inhibited the nuclear
translocation of signal transducer and activator of transcrip-
tion-1 (Stat1), which modulates gene expression in response to
IFN stimulation (Figure 2B). VEGF pretreatment of HUVECs
also was able to counteract the inhibitory effect of IFNa on OV
infection (Figure 2C).
We performed a parallel analysis on publishedmicroarray data
(Suehiro et al., 2010) to identify potential mediators of innate anti-
viral suppression in VEGF-treated, non-infected HUVECs. Our
analysis focused on a selective subset of regulators with known
activator (n = 569) or repressor (n = 456) functions (Figure S2D).
The transcriptional repressor PRD1-BF1, also known as Blimp1
in the mouse (Keller and Maniatis, 1991), emerged as the most
interesting candidate due to elevated mRNA expression levels
(8-fold increase) upon VEGF treatment, and its immunological
function in other cell systems.
VEGF165 Upregulates the Transcription Repressor
PRD1-BF1 in Human Endothelial Cells
We hypothesized that VEGF-induced PRD1-BF1 expression
could suppress the antiviral response in endothelial cells, as
suggested by our GO enrichment analysis. Both qRT-PCR (Fig-
ure 3A) and western blot analysis (Figure 3B) revealed that basal
expression of PRD1-BF1 is barely detectable in HUVECs, but is
induced up to 50-fold in a dose-dependent manner in response
to VEGF165. In both HUVECs and HDMECs, the induction of
PRD1-BF1 by VEGF165 was abrogated by bevacizumab (Fig-
ure 3C) and suppressed by blocking VEGFR signaling using
kinase inhibitors, such as brivanib and sunitinib (Figure 3D).
Other direct activators of VEGFR2 were capable of inducing
PRD1-BF1 expression, including CM from MC38 cells (Fig-
ure 3D), the hVEGF121 isoform (Figure 3E), as well as VEGF-E
(Figure 3E), a distinct family member that is encoded by the
Orf parapoxvirus that does not bind to VEGFR1/Flt-1 (Meyer
et al., 1999). Growth factors that induce similar downstream
signaling events, such as epidermal growth factor (EGF; Fig-
ure 3F), fibroblast growth factor 1 or 2 (FGF1 and FGF2; Fig-
ure 3F), or placental growth factor (PlGF; data not shown), which
binds to VEGFR1 (Matsumoto and Claesson-Welsh, 2001), were
unable to induce PRD1-BF1 expression in either HUVECs or
normal human GM38 fibroblasts (Figure S3). Lastly, we
confirmed that oncolytic vaccinia virus infection of human
primary endothelial cells had no obvious impact on the VEGF-
mediated induction of PRD1-BF1 (Figure 3G).
PRD1-BF1 Sensitizes HUVECs to Oncolytic Virus
Infection by Suppressing the Antiviral Response
Transfection of a smart pool of small interfering RNA (siRNA)
selectively targeting PRD1-BF1 in HUVECs resulted in >85%
knockdown of PRD1-BF1 protein induced by VEGF (Figure 4A).
Upon infection with oncolytic vaccinia virus, we observed that
PRD1-BF1 knockdown in HUVECs led to a dramatic reduction
in GFP transgene expression and viral titers compared to the un-
treated, and non-targeting, scrambled siControl-transfectedCancer Cell 28, 210–224, August 10, 2015 ª2015 Elsevier Inc. 211
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Figure 2. VEGF Signaling in Endothelial
Cells Promotes a Repression of the Type I
IFN Immune Response
(A) Gene ontology (GO) analysis of VEGF-respon-
sive genes in WyTK/GFP+-infected endothelial
cells. Statistically significant enrichment for GO
categories involved in cellular division (left) and
type I IFN immune response (right) are shown.
(B) Immunoblot analysis of indicated proteins in
nuclear and cytoplasmic fractions from HUVECs
treated with or without VEGF165 overnight and
either mock infected or infected with oncolytic
WyTK/GFP+ for 48 hr is shown.
(C) Viral titers of WyTK/GFP+-infected HDMEC
treated with VEGF165 and IFNa as indicated.
Values represent mean titers ± SEM (n = 3); *p <
0.05, **p < 0.01 by Student’s t test.
See also Figure S2.cells (Figures 4B and 4C). PRD1-BF1 knockdown in HUVECs
had no impact on either cell viability or VEGF-mediated in-
creases in proliferation (Figures 4D and S4A).
PRD1-BF1 is a known transcriptional repressor, so we per-
formed microarray analysis on WyTK/GFP+-infected HUVECsFigure 1. VEGF Sensitizes Tumor Vasculature to Infection by Oncolytic Viruses
(A) Representative fluorescent confocal micrograph shows subcutaneously allografted MC38-derived tumo
within a window chamber of a C57/BL6 mouse injected with anti-CD31-APC and imaged after 3 days (n = 3
(B) IHC of oncolytic vvDD-RFP-infected MC38 tumors for CD31 and vvDD from (A). The absolute number of
absence () of vvDD staining within these blood vessels (see insets) were quantified 3 days post-vvDD. Value
(n = 3), kidney (n = 3), and tumor (n = 3). Scale bar represents 100 mm.
(C) Representative fluorescent micrographs of vvDD-RFP-infected (red) HUVECs grown in untreated media
mouse VEGF-A-supplemented media (mVEGFA). HUVECs were pretreated with VEGFR inhibitor brivanib at 1
(D) Viral titers of experiment described in (C). Values represent mean titers ± SEM; *p < 0.05, ***p < 0.001 by
(E) Representative fluorescent micrographs of WyTK/GFP+-infected (green) HUVECs grown in untreated me
or human VEGF-supplementedmedia (hVEGF165). HUVECs were treated with or without the VEGF inhibitor be
represents 50 mm.
(F) Viral titers of experiment described in (E). Values represent mean titers ± SEM; **p < 0.01, ***p < 0.001 b
(G) Immunoblot analysis of VEGFR2 phosphorylation in HUVECs exposed to mock-treated media (untreated
or Caki-1 CM, with or without bevacizumab (500 ng/ml) as indicated, is shown (n = 3; pooled).
(H–J) Viral titers of WyTK/GFP+-infected HDMEC (H), MDA-MB-231 (I), or Caki-1 (J) treated with vehicle (Mo
where indicated. (Inset) VEGFR2 expression in each cell line by immunoblot is shown. Values represent m
Student’s t test.
See also Figure S1.
Cancer Cell 28, 210–224pretreated with VEGF165 and transfected
with siPRD1-BF1 or Control siRNA.
Although PRD1-BF1 knockdown had a
marginal impact on the global transcrip-
tome, approximately 60% of genes
repressed by VEGF (>2-fold repression,
n = 183/22,693) were at least partially
rescued by siPRD1-BF1 knockdown
(>1.5-fold induction, n = 111/183). There
is a significant overlap between the two
datasets (p value < 1E122), indicating
that a large proportion of VEGF-medi-
ated transcriptional repressor activities
are regulated by PRD1-BF1 under these
conditions (Figure 4E). A similar overlap
was observed for genes induced >2-
fold by VEGF (n = 199) and repressedat least 1.5-fold by PRD1-BF1 knockdown (60/199), but
to a much lesser degree (p value < 1E45). Genes within
this dataset include PRD1-BF1, which was induced 6-fold
by VEGF treatment and repressed 3.6-fold following gene
knockdown.r infected with oncolytic vaccinia virus (vvDD)-RFP
). Scale bar represents 100 mm.
CD31+ blood vessels as well as the presence (+) or
s represent mean ± SEM per field; lung (n = 3), liver
(Mock), MC38-conditioned media (MC38 CM), or
0 nMwhere indicated. Scale bar represents 50 mm.
Student’s t test.
dia (Mock), Caki-1-conditioned media (Caki-1 CM),
vacizumab at 500 ng/ml where indicated. Scale bar
y Student’s t test.
), human VEGF165-supplemented media (VEGF165),
ck) or VEGF165 along with bevacizumab (500 ng/ml)
ean titers ± SEM (n = 3); *p < 0.05, **p < 0.01 by
, August 10, 2015 ª2015 Elsevier Inc. 213
Figure 3. VEGF Upregulates the Transcription Repressor PRD1-BF1 in Human Endothelial Cells
(A) RT-PCR analysis of RNA harvested from HUVECs treated with the indicated concentrations (0–100 ng/ml) of VEGF165 following 24 hr of exposure. PRD1-BF1
expression fold changes were normalized to GAPDH. Values represent fold change ± SEM (n = 4); *p < 0.05, ***p < 0.001 by Student’s t test.
(B) Immunoblot analysis of PRD1-BF1 in HUVECs treated with 0–200 ng/ml VEGF165 for 24 hr. Densitometry values for PRD1-BF1 bands were normalized to
a-tubulin (n = 3; pooled).
(C) RT-PCR analysis of RNA harvested from HUVECs or HDMECs treated with VEGF165 or VEGF165 preincubated 30 min with 500 ng/ml bevacizumab for 24 hr.
Expression fold changes were calculated as in (A). Values represent fold change ± SEM (n = 4); *p < 0.05 by Student’s t test.
(D) Immunoblot analysis of PRD1-BF1 in HUVECs treated with mVEGFA or MC38 CM. HUVECs were pretreated with DMSO, sunitinib (4 mM), or brivanib (10 nM),
where indicated. Densitometry values for PRD1-BF1 bands were normalized to a-tubulin (n = 3; pooled).
(E) Immunoblot of HUVECs treated with VEGF165, VEGF-E from Orf virus, or VEGF121 for 48 hr is shown.
(F) Immunoblot of HUVECs treated with VEGF165, EGF, FGF1, or FGF2 for 48 hr is shown.
(G) HDMECs were treated with VEGF165 with/without 500 ng/ml bevacizumab, where indicated, for 24 hr, and subsequently mock infected or infected with
WyTK/GFP+. Cell lysates were harvested 24 hr post-infection (n = 3; pooled) and analyzed by immunoblotting.
See also Figure S3.We examined the gene ontologies associated with the subset
of targets that was defined as being repressed >2-fold by VEGF
treatment and rescued at least 1.5-fold following PRD1-BF1
knockdown. In Figures 4F and 4G, these genes are significantly
associated (2.9–263 enrichment, p value < 1E8) with antiviral
responses, specifically type I IFN signaling. Examples of these214 Cancer Cell 28, 210–224, August 10, 2015 ª2015 Elsevier Inc.antiviral targets (Figure 4G in red) include RSAD2, OAS1,
OAS3, CFH, CXCL10, DDX60, STAT2, and IFIT1. In contrast, of
57 cell-cycle genes induced by VEGF (>2-fold increase), only
one gene (MND1) changed upon PRD1-BF1 knockdown (Fig-
ure S4A). Furthermore, our dataset reveals a striking overlap
between genes repressed by VEGF, or rescued following
PRD1-BF1 knockdown in the context of vaccinia infection, with
those induced by IRF1, a key player in antiviral immunity (Fig-
ure S4B; Schoggins et al., 2011). Taken together, these results
support our previous observation that PRD1-BF1 knockdown
has no effect on VEGF-induced cell division (Figure 4D) and
that VEGF-induced mitogenic and immunosuppressive path-
ways are not coordinately regulated at the transciptional level.
These data support the notion that PRD1-BF1 is a master regu-
lator of an immunosuppressive branch of VEGF signaling in
endothelial cells.
VEGF-Mediated PRD1-BF1 Induction Occurs through a
VEGFR2/Erk/Stat3 Signaling Axis
We carried out experiments to delineate the molecular effectors
that link VEGFR2 to PRD1-BF1 expression in endothelial cells.
Stat3 is a known driver of oncogenesis that impacts both innate
and adaptive immunity (Yu et al., 2007). Extracellular regulated
kinase 1/2 (Erk1/2) is required for maximal transcriptional activity
of Stat3 through induction of phosphorylation at serine 727
(Turkson et al., 1999), and was shown to be required for Stat3-
mediated differentiation of B cells through PRD1-BF1 (Barnes
et al., 2012; Yasuda et al., 2011). In primary endothelial cells,
treatment with VEGF165 resulted in rapid phosphorylation of
both Stat3 and Erk1/2 prior to the induction of PRD1-BF1
expression (Figure 5A). Compounds that block Stat3 phosphor-
ylation and dimerization, such as S3I-201 (Siddiquee et al.,
2007), inhibited VEGF-mediated PRD1-BF1 induction, nuclear
localization, and sensitization to oncolytic vaccinia virus (Figures
5B–5E and S5A). A comparable effect was observed with the
cisplatin analog CPA7 known to inhibit Stat3-DNA binding
(data not shown). Similarly, inhibition of Erk1/2 signaling in
HUVECs with U0126 blocked PRD1-BF1 expression (Figures
5B–5E, S5B, and S5C). Our data further revealed that PRD1-
BF1 induction also can be abrogated by these signaling inhibi-
tors in HUVECs chronically treated with VEGF, to mimic the
context of pathological angiogenesis within tumor vasculature
(Figure S5D). Taken together, these data support a model in
which PRD1-BF1-mediated innate immunosuppression in endo-
thelial cells is transduced through the VEGF-A/VEGFR2/Erk/
Stat3 signaling axis.
PRD1-BF1/Blimp1 Is Expressed in Tumor Vasculature
upon VEGFR2 Signaling
We examined PRD1-BF1 levels (Blimp1 in the mouse) within the
remodelling vasculature of a tumor using immunohistochemical
staining and found that this transcriptional repressor was de-
tected in approximately 80% of the blood vessels in MC38
tumors compared to the normal vasculature of the lungs
(34%), liver (19%), and skin (16%) (Figures 6A and 6B). Similar
results were obtained in nude mice bearing Caki-1 tumors (not
shown).
To determine if Blimp1 upregulation observed within MC38 tu-
mor vasculature is triggered by chronic VEGF/VEGFR2 signaling,
tumor-bearing mice were treated with B20-4.1.1, a monoclonal
antibody specific to murine VEGF (Liang et al., 2006), or
DC101, a neutralizing antibody to VEGFR2 that blocks ligand-
induced receptor activation (Witte et al., 1998). Tumors har-
vested 24 hr post-treatment were stained for Blimp1 (Figure 6C).
Quantification of Blimp1-positive vessels revealed a markedreduction upon treatment with either B20-4.1.1 (42% versus
68% for PBS-treated controls) or DC101 (24% versus 76% for
Rat IgG-treated controls; Figure 6D). Similar effects were
observed when 80 mg/kg sunitinib was administered via oral
gavage for 18 hr (32% versus 76% for DMSO-treated controls,
Figures S6A and S6B). Blimp1 levels gradually returned to
pretreatment levels within 72 hr of administration of either B20-
4.1.1 or DC101, likely due to a rebound in VEGF levels (Fig-
ure S6C). In addition, mice were treated i.v. with 5 mg/kg
CPA7, a potent Stat3 inhibitor (Assi et al., 2014), or vehicle
(diluted DMSO) for 24 hr. Immunohistochemical analysis (Figures
6C and 6D) demonstrated that, similar to VEGF/VEGFR inhibi-
tors, CPA7 led to a significant reduction in Blimp1-positive ves-
sels (25% versus 71% for DMSO-treated controls). Thus, VEGF/
VEGFR/Stat3 signaling significantly contributes to increased
Blimp1 levels within MC38 tumor vasculature.
Blimp1 Expression in Tumor Vasculature Predicts
Sensitivity to Oncolytic Vaccinia Virus Infection of
Murine Adenocarcinomas
MC38 tumor-bearing C57BL/6 mice were treated with B20-4.1.1
or DC101 intraperitoneally (i.p.) or CPA7 i.v. for 22 hr then admin-
istered 1E9 PFU vvDD. Then, 3 days later, mice were sacrificed
and tumors were processed for histological analysis. Vaccinia
staining revealed a pronounced block in vvDD infection (Fig-
ure 7A) when Blimp1 was suppressed (Figures 6C and 6D).
Quantification of vaccinia-infected vessels (Figure 7B) revealed
a significant reduction following treatment with B20-4.1.1 (15%
versus 26% for PBS-treated controls), DC101 (11% versus
36% for Rat IgG-treated controls), or CPA7 (12% versus 34%
for diluted DMSO controls), demonstrating the importance of
vessel infection to both virus delivery and spread within the
tumor.
If Blimp1 expression sensitizes tumor vasculature to oncolytic
vaccinia virus infection via the suppression of IFN signaling, we
predicted that, in animals lacking an IFN response, blocking
VEGF signaling would not impede virus replication. We tested
this idea using C57/BL6 mice deficient in the receptors for
type I IFN (Ifnar1/ mice; Robinson et al., 2012). Following im-
plantation of MC38 tumors into Ifnar/ mice, we administered
B20-4.1.1 or PBS and then 22 hr later infected with vvDD. IHC
and quantification of vaccinia-positive vessels 3 days after virus
delivery revealed no significant impact of the anti-VEGF antibody
in Ifnar/ mice (Figures S7A–S7D, 40% versus 31% for PBS
controls or 52% for both treatment conditions after immunofluo-
rescent costaining of sections for CD31 and vaccinia) compared
to WTC57BL/6 mice, which have intact IFN signaling (Figures 7A
and 7B).
We examined the effects of vvDD-mediated infection of blood
vessels in the MC38 model. Cleaved caspase-3 and serial H&E
staining of MC38 tumor sections revealed an overlap between
vaccinia infection and areas of cell death and necrosis, including
within vessel structures (Figure 7C). Taken together, our data
demonstrate the fundamental importance of the VEGF/Blimp1
axis in modulating the permissiveness of tumor blood vessels
to vaccinia infection and destruction. The dampening of IFN
signaling within tumor vasculature creates a gateway for entry
and spread into the tumor of systemically administered oncolytic
virus.Cancer Cell 28, 210–224, August 10, 2015 ª2015 Elsevier Inc. 215
Figure 4. PRD1-BF1 Sensitizes HUVECs to Oncolytic Virus Infection by Suppressing the Antiviral Response
(A) Immunoblot analysis of HUVECs transfectedwith siControl or siPRD1-BF1; then, after 24 hr, treatedwith VEGF165 where indicated; and harvested 24 hr later is
shown (n = 3; pooled sextuplets).
(B) HUVECs were transfected with siControl or siPRD1-BF1, 24 hr later treated with or without VEGF165, then infected with oncolytic virus WyTK
/GFP+ and
titered 48 hr post-infection (n = 3). Values represent mean titers ± SEM; *p < 0.05 by Student’s t test.
(C) Representative micrographs of siControl- and siPRD1-BF1-transfected HUVECs infected with WyTK/GFP+ (green) 48 hr post-infection. Scale bars
represent 50 mm (top panels) and 20 mm (lower phase contrast panels).
(D) Trypan blue cell viability assay of siControl- and siPRD1-BF1-transfected HUVECs treated with VEGF165. Cell viability wasmeasured 24 hr post-VEGF. Values
represent mean ± SEM (n = 3); *p < 0.05, ***p < 0.001 by Student’s t test.
(E) Histogram illustrates the fold change in gene expression in HUVEC following PRD1-BF1 knockdown for all genes (blue, n = 22,693) or those sub-classified as
repressed over 2-fold by VEGF (red, n = 183) after oncolytic vaccinia virus infection.
(legend continued on next page)
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VEGF Mediates Sensitivity to Oncolytic Vaccinia Virus
Infection in Wound-Healing Models
There aremany parallels in themolecular signals that drive angio-
genesis within the tumor microenvironment and those that pro-
mote wound healing, with the former being persistent and the
latter transient and tightly controlled (Scha¨fer and Werner,
2008). We hypothesized that, similar to a tumor, the remodelling
vasculature of a healing wound would be equally susceptible to
OV infection. Indeed we found in an in vitro wound-healing assay
that VEGF165 promoted vaccinia virus infection selectively along
the leading edge of the wound and treatment with bevacizumab
was able to abrogate this effect (Figure 8A). In this model, loss of
cell-cell contact bymechanical disruptionof thequiescentmono-
layer can overcome the blockade of VEGF receptor signaling
moderated by adherens junctions between endothelial cells,
leading to migration and wound closure (Dejana, 2004).
We compared sparse and confluent HUVEC cultures for their
ability to support vaccinia replication following VEGF165 pretreat-
ment. VEGF165 enhanced viral titers by over 10-fold in sub-
confluent cells, but provided little to no enhancement in HUVECs
grown to high cell densities (Figures S8A and S8B). Immunofluo-
rescence staining of mechanically wounded cells revealed that
PRD1-BF1 expression is localized to the leading edge of awound
uponVegf165 treatment, in cells that are infectedbyvaccinia virus
(Figure 8B). Scratch assays performed with PRD1-BF1 knock-
down cells further indicated that PRD1-BF1 does not impact
HUVECs wound closure per se (Figures S8C and S8D). We per-
formed an in vivo assay where dorsal incisions were made on
C57BL/6 mice and IHC for Blimp1 was performed on wounded
skin collected at 1, 3, and 5 days post-surgery (Figure 8C). Quan-
tification of positively stained vessels revealed a significant and
transient increase in Blimp1 at 1 and 3 days post-wounding, re-
turning to baseline levels after 5 days (Figure 8C). We injected
vvDD 3 days after wounding and found that 18% of the vessels
in the wounded area were infected with vaccinia virus, while no
virus was detected in uninjured skin (Figure 8D). Taken together,
our data reveal that VEGF-mediatedPRD1-BF1 inductionand im-
munesuppression occurswithin the context of twomajor typesof
remodelling vasculature, wounded and malignant.
DISCUSSION
Oncolytic viruses are engineered to specifically infect malignant
cells yet, unexpectedly, also can infect normal vessel-forming
endothelial cells found within the tumor bed in both animal
models and cancer patients. The sensitization of vascular endo-
thelial cells to oncolytic virus infection is dependent upon a
signaling network that links the pro-angiogenic growth factor
VEGF to anti-viral programs regulated by IFNs. VEGF not only
is a key driver of tumor vascularization and metastasis (Leung
et al., 1989), but also is thought to play a role in repressing the
generation of innate and adaptive immune responses against
the tumor (Motz and Coukos, 2011). The transcriptional profiling(F) Enriched GO term processes of VEGF-repressed genes that were de-repres
p values in parentheses are the hypergeometric p values following correction for
(G) Gene expression heatmap of VEGF-repressed subset of genes. Representatio
BF1 knockdown (siPRD1-BF1) is shown. Gene symbols in red are associated wi
See also Figure S4.presented here is consistent with a dual role for VEGF in stimu-
lating vascular endothelial cell proliferation while simultaneously
suppressing cellular innate anti-viral immune responses. PRD1-
BF1 is the key mediator of VEGF suppression of innate
immune responses in vascular endothelial cells, but is not neces-
sary for VEGF-driven mitogenic signaling pathways. It was
previously demonstrated that PRD1-BF1/Blimp1 competes for
the same binding sites recognized by IFN regulatory factors
IRF1 and IRF2 in myeloma cells (Doody et al., 2007). Indeed,
the PRD1-BF1 consensus binding sequence (A/C)AG(T/C)
GAAAG(T/C)(G/T) is almost identical to the IRF-E sequence
bound by IRF1, known to transcriptionally activate the type I
IFN program in response to most viruses (Schoggins et al.,
2011). In the studies described here using human primary endo-
thelial cells, we uncovered a striking overlap between IRF1 and
PRD1-BF1 target genes. Our observation that VEGF treatment
of endothelial cells antagonizes the anti-viral properties of IFNa
supports a model in which VEGF-induced PRD1-BF1 protein
antagonizes IRF at the promoters of key antiviral genes.
The VEGF-signaling pathway appears to be exploited by
particular virus families during natural infections. For example,
tissues infected by cytomegalovirus and human herpes virus
cause accelerated pathologic angiogenesis due to virus-
induced overexpression of cellular VEGF (Masood et al., 2002;
Reinhardt et al., 2005). Members of the Parapox family, such
as oncolytic Orf (Rintoul et al., 2012; Wise et al., 1999), Pseudo-
cowpox (PCPV) (Ueda et al., 2003), and Bovine papular stomati-
tis virus (Inder et al., 2007), all encode VEGF homologs. Our
observation that anti-VEGF therapies inhibit OV propagation in
endothelial cells suggests that anti-angiogenic therapies may
reduce virus replication and spread for some types of natural
infections.
Specific targeting of VEGF, its receptor, or Stat3, lowers
PRD1-BF1/Blimp1 expression in tumor vasculature and inhibits
the ability of a clinically relevant oncolytic virus to productively
infect and destroy blood vessels and subsequently spread
throughout the tumor bed. In normal remodelling of vasculature
after wounding, it is known that the gene expression signatures
are strikingly similar to those found in tumors (Chang et al., 2004;
Pedersen et al., 2003; Riss et al., 2006), and neovasculariza-
tion in healing wounds resembles that of the disorganized, rudi-
mentary-like, permeable vascular networks found in tumors
(Wietecha et al., 2013). We found a transient increase in Blimp1
expression following dorsal skin wounding that is co-incident
with susceptibility of remodelling normal vessels to OV infection,
although this has no impact on the rate of wound healing (J.A.
McCart, personal communication). In scratch-based in vitro
wound-healing assays, oncolytic vaccinia virus selectively in-
fects the cells expressing PRD1-BF1 at the leading edge. How-
ever, in conditions that simulate endothelial interactions in
normal resting blood vessels, i.e., confluent cells, oncolytic
vaccinia virus infectivity of HUVECs is markedly reduced even in
the presence of VEGF165. It is likely that tightly associatedsed (>1.5-fold) by PRD1-BF1 knockdown upon oncolytic virus infection. The
multiple hypothesis testing (Benjamini Hochberg method).
n of VEGF165-repressed genes (siControl) and their de-repression upon PRD1-
th the GO terms depicted in (F). Genes not found in GOrilla are not shown.
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Figure 5. VEGF-Mediated PRD1-BF1 Induction Occurs through a VEGFR2/Erk/Stat3 Signaling Axis
(A) Whole-cell lysates were harvested from HUVECsmock treated or treated with VEGF165 at the indicated time points (n = 3; pooled) and then immunoblotted as
indicated.
(B) HUVECs were treated with DMSO (Mock), bevacizumab (bev, 500 ng/ml), brivanib (10 nM), S3I-201 (75 mM), or U1026 (10 mM) for 30 min prior to stimulation
with VEGF165. Whole-cell lysates were harvested 48 hr later (n = 3; pooled) and immunoblotted as indicated.
(C) Representative immunofluorescent micrographs of PRD1-BF1 localization in HUVECs grown on glass coverslips and treated as in (B). Scale bar
represents 20 mm.
(D) HUVECs were treated as in (B) and infected 24 hr later with WyTK/GFP+. Representative fluorescent images of infected HUVECs (green) were captured at
48 hr post-infection. Scale bar represents 50 mm.
(E) Viral titers of experiment described in (D). Values represent mean titers ± SEM; *p < 0.05, **p < 0.01 by Student’s t test.
See also Figure S5.endothelium of normal blood vessels contributes to the suppres-
sion of VEGF signals and resistance to infection. It is perhaps
axiomatic that oncolytic virus delivered systemically must exit218 Cancer Cell 28, 210–224, August 10, 2015 ª2015 Elsevier Inc.blood vessels to gain access to the tumor bed or normal tissues
and that vascular endothelial cells constitute a significant barrier
to virus extravasation. Our data support the idea that normal
Figure 6. PRD1-BF1/Blimp1 Expression in Tumor Vasculature Is Dependent on VEGF-VEGFR2 Signaling
(A) IHC for Blimp1 expression in normal tissues and MC38 tumors in C57BL/6 mice. The red plus and minus indicate the presence and absence, respectively, of
Blimp1 expression. The black plus indicates the location of tissue vasculature. Scale bars represent 200 mm.
(B) Percentage of Blimp1-positive blood vessels in normal and MC38 tumor tissues from (A). Values represent proportional mean ± SEM calculated from bio-
logical triplicates; skin (n = 3), liver (n = 3), lung (n = 3), and tumor (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t test.
(C) Blimp1 expression in MC38 tumor vessels from mice treated with B20-4.1.1, DC101, or CPA7. Representative serial sections of MC38 tumors from control-
treated (top: PBS [shown], IgG, or DMSO) or drug-treated mice, as indicated, were analyzed by Blimp1 IHC or H&E staining 24 hr after administration. Scale bar
represents 200 mm.
(D) Percentage of Blimp1-positive blood vessels over total vessels in MC38 tumors from mice treated in (C), as indicated. Values represent proportional mean ±
SEM; n = 6 tumors per group; p values were derived by Student’s t test.
See also Figure S6.
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Figure 7. Targeting PRD1-BF1/Blimp1 in Tumor Vasculature Suppresses vvDD Infection of MC38 Tumors
(A) Representative H&E and IHC for vaccinia virus images of MC38 tumor sections frommice treated as indicated, for 22 hr prior to i.p. administration of 1E9 PFU
vvDD-mCherry. IgG controls (shown) are comparable to PBS or DMSO controls. Tumors were extracted 3 days post-vvDD. Insets representingmagnified images
of a representative area enable visualization of infected (+) or uninfected () blood vessels. The plus in H&E images indicate tumor vasculature. Scale bar
represents 200 mm unless indicated otherwise.
(B) Percentage of vvDD-positive blood vessels fromMC38 tumor-bearing mice treated in (A). Values represent proportional mean ± SEM, n = 5 tumors per group;
p values were derived by Student’s t test.
(C) H&E and IHC analysis as indicated of MC38 tumors from mock-treated mice administered 1E9 PFU vvDD-mCherry in (A). Images at the right show higher
magnification of the indicated area in the corresponding left images. Arrows in the right indicate representative areas of tumor vessel destruction. Scale bars
represent 1 mm (left) and 100 mm (right).
See also Figure S7.
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Figure 8. Blimp1 Mediates Sensitivity to
Oncolytic Virus Infection in the Wound-
Healing Paradigm
(A) Representative immunofluorescence images of
a monolayer of HUVECs that was mechanically
scratched and treated with VEGF165 or VEGF165
with 500 ng/ml bevacizumab, infected with
WyTK/GFP+, and imaged 24 hr post-infection.
Scale bar represents 200 mm.
(B) Representative immunofluorescence images of
amonolayer of HUVECs grown on glass coverslips
that was mechanically scratched, treated with
VEGF165, infected with WyTK
/GFP+, and then
fixed 24 hr post-infection and stained for PRD1-
BF1. Scale bar represents 100 mm (left) or 50 mm
(right).
(C) The bar graph presents the percentage of
Blimp1-positive vessels in normal C57BL/6 mouse
skin at 1, 3, and 5 days post-wounding. Values
represent proportional mean ± SEM, n = 3 tumors
per group; *p < 0.05, **p < 0.01 by Student’s t test.
The images show representative results of IHC for
Blimp1 from animals sacrificed 1 or 5 days post-
wounding. The red plus and minus indicate the
presence and absence, respectively, of Blimp1
expression in wounded vasculature. Scale bar
represents 200 mm.
(D) IHC of oncolytic vvDD-RFP-infected (day 3)
wounded tissue for CD31 and vvDD. The presence
(+) of CD31 or vvDD staining in blood vessels was
quantified (n = 3). Values represent proportional
mean ± SEM. Scale bar represents 100 mm.
See also Figure S8.vasculaturedoes indeedactasabarrier tooncolytic virus infection
of normal tissues; however, ill-formed tumor vasculature bathed in
VEGF supports oncolytic virus replication and acts as conduit for
virus spread from the vascular system into the tumor bed.
Oncolytic viruses are a unique platform of therapeutics de-
signed to take advantage of the repressed innate anti-viral state
commonly found within cancer cells, but in addition can target
vascular endothelial cells bathed in VEGF. Our findings suggest
that characterization of the VEGF and PRD1-BF1 status within
the tumor may be a valuable marker for the identification of pa-
tients who may be more amenable to OV therapy.
EXPERIMENTAL PROCEDURES
Detailed experimental information is provided in the Supplemental Experi-
mental Procedures.
Virus
The oncolytic version of Wyeth-based vaccinia virus (WyTK/GFP+) encoding
GFP and the mouse-adapted vvDD-RFP or vvDD-mCherry were described
previously (Kim et al., 2006) and quantified by plaque assay on U2OS cells.
Cell Culture Models
HUVECs and HDMECs were purchased from Lonza and grown in endothelial
or microvascular endothelial cell growth medium-2 (Lonza). MDA-MB-231,
Caki-1, GM38, and MC38 cells were purchased from ATCC and maintained
in either DMEMorMcCoys 5Amedium (for Caki-1) containing 10% fetal bovineserum (FBS). HUVECs, HDMECs, and GM38 cells were not passaged more
than three times since resuscitation.
Subconfluent cells were synchronized in basal MCDB131 medium (Gibco/
Invitrogen) with 0.5% FBS and pulsed with indicated concentrations of growth
factors. Small molecule inhibitors were added at the indicated concentrations,
30 min prior to growth factor treatment. For viable counts, trypan blue exclu-
sion assay was performed on the Vi-CELL counter (Beckman Coulter).
For in vitro wound-healing assays, HUVECs were grown on glass coverslips
until confluent, treated with VEGF165, scratched with a sterile cell scraper, and
infected with WyTK/GFP+ at MOI 0.01 for 24 hr.
Fluorescence Microscopy
Viral infection of cells was determined by direct detection of GFP or RFP fluo-
rescence 24–72 hr post-infection, as indicated, using an Axiovert S100 fluores-
cence microscope (Carl Zeiss). For indirect immunofluorescent detection,
paraformaldehyde-fixed cells were permeabilized, blocked, incubated with
antibodies, and mounted with Prolong anti-fade (Dako) with DAPI. Images
were collected using the Zeiss ImagerM1microscope equippedwith AxioCam
HRm camera (Carl Zeiss).
Mouse Models and Treatment Protocols
For bio-distribution of vvDD-RFP in normal, tumor, and wounded vasculature,
3E5 MC38 colon carcinoma cells were used in a window chamber model as
previously described (Guba et al., 2002; Ottolino-Perry et al., 2014). 1E9
PFU vvDD was administered i.p. and organs harvested after 3 days. For
disruption of VEGF/VEGFR signaling, C57BL/6 mice (Charles River Labora-
tories) were treated i.p. with B20-4.1.1 (Genentech), DC101 (Bio X Cell), Rat
IgG control (Sigma), or PBS. CPA7 was a generous gift from Dr. Leda RaptisCancer Cell 28, 210–224, August 10, 2015 ª2015 Elsevier Inc. 221
and administered in diluted DMSO, i.v., as described previously (Assi et al.,
2014; Littlefield et al., 2008).
IHC
Organs were fixed in 10% formalin and processed for paraffin embedding.
Blocks were serially sectioned and stained with H&E or for specific target
antigens: PRDM1/Blimp1 middle region antibody (Aviva Systems Biology),
cleaved caspase-3 (NewEngland Biolabs/Cell Signaling Technology), vaccinia
polyclonal antibody (quartett; Breitbach et al., 2011a, 2011b, 2013), and CD31
(Santa Cruz Biotechnology), using Vectastain Elite ABC peroxidase kits (rabbit
or goat IgG). Slides were imaged using the Aperio ScanScope (Axiovision
Technologies) and Aperio ImageScope software. For vessel quantification,
the number of Blimp1- or vaccinia-positive vessels were defined as a percent-
age of total vessels counted (n = 20–100 per tumor section over five fields) from
serial H&E- or CD31-stained sections.
Western Blotting
Cell lysis and fractionation experiments were performed as previously
described (Vultur et al., 2004). Following protein determination by Bradford
assay (Bio-Rad Protein Assay Solution), 10–20 mg of clarified cell extract
was analyzed using the NuPAGE SDS-PAGE Gel system (Invitrogen). Blots
were cut into strips and probed with specific antibodies. Bands were visual-
ized using SupersignalWest Pico Chemiluminescent substrate (ThermoScien-
tific Pierce).
qRT-PCR
RNA extraction was performed from cells grown in six-well dishes using
QIAGEN QiaShredder columns and the QIAGEN RNeasy kit; 2 mg RNA
was converted to cDNA with Superscript II Reverse Transcriptase (Invitro-
gen). Real-time PCR reactions were performed with the QuantiTect SYBR
Green PCR kit (QIAGEN) on a Rotor-gene RG-3000 (Corbett Research).
Optimal threshold and reaction efficiency were determined using the
Rotor-gene software. Melt curves for PRDM1 exhibited a single peak, indi-
cating specific amplification, which also was confirmed by agarose gel. Ct
values were determined using the Rotor-gene software at the optimal
threshold. Gene expression relative to GAPDH was calculated using the
method described previously (Pfaffl et al., 2004). Fold induction or PRDM1
was calculated relative to the untreated control. Primers were designed using
Primer 3 version 4.0.
PRD1-BF1 Knockdown for Affymetrix Analysis
HUVECs in six-well dishes were transfected with SMARTpool ON-
TARGETplus PRDM1 siRNA, an siRNA scrambled control, or oligofectamine
(Invitrogen) alone. Then, 24 hr later, cells were treated with VEGF overnight
and infected, as described; 24 hr later, cells from quadruplicate wells
were collected and RNA extracted, diluted to a concentration of 100 ng/ml,
and pooled at equal ratios. The quality of the final samples was confirmed
using an Agilent Bioanalyzer. Samples were hybridized to an Affymetrix
human gene 2.0 ST array according to the manufacturer’s instructions. Probe-
set filtering and data normalization were performed using Affymetrix Expres-
sion console. Normalized data were filtered by selecting the probeset with
the highest average signal for a single ensemble gene identifier and removing
all genes with a signal in the bottom quartile of the dataset. Gene ontology
enrichments were performed using GOrilla (Eden et al., 2009).
Statistical Analysis
Statistical analyses were performed on Microsoft Excel statistical analysis
software package. All p values considered significant were p < 0.05. All
p values reported for the GO term analysis were calculated using the hyper-
geometric model following correction for multiple hypothesis testing using
the Benjamini and Hochberg method.
Animal Approval
Animal experiments were approved and performed in accordance with institu-
tional guidelines review board for animal care (University of Ottawa ethical
board and Animal Care Centre, University Health Network). Survival endpoint
criteria were defined as severe abdominal distension, cachexia, or develop-
ment of subcutaneous injection site tumor >1.5 cm in diameter.222 Cancer Cell 28, 210–224, August 10, 2015 ª2015 Elsevier Inc.ACCESSION NUMBERS
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